WASHINGTON, June 28, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company is presenting updates on its Phase 3 Allovectin® immunotherapeutic for metastatic melanoma and its preclinical herpes simplex type 2 (HSV-2) vaccine at the BIO International Convention (Washington, DC – June 27-30).
